Innovation For Life

Defeating Pain, Controlling Inflammation

Our Company
We are a pre-clinical stage pharmaceutical company using our proprietary NCE to treat acute and chronic inflammation. We will offer our products for licensing post Ph II studies in high unmet need indications.

Our Science

Our NCE target the endocannabinoid and cyclooxygenase pathways. Our technology allows intravenous, topical and intranasal delivery.

Our Indications

Our NCE will benefit patients suffering the pain and inflammation of dry eye syndrome, and those experiencing pain after surgery.

CONTACT US

Phone: 514 883 3447

Email: info@tallcinc.com

NEWS

TALLC issues new Corporate Presentation

Dr. Damon Smith at Biotech Show Case

TALLC at the Ophthalmology Innovation Summit

TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001

Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001

TALLC and IACTA to present at the H.C. Wainwright Bioconnect Conference: January 10-13, 2022
https://lnkd.in/g5ZhR2Yn

TALLC will present details of the SmartCelle insoluble drug delivery platform for ocular, parenteral and oral delivery and an update on t…https://lnkd.in/gAwAqwnQ

Load More...
TALLC Innovation in Vision

© TALLC Inc. 2020